Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Kaken Initiates Voluntary Partial Recall of Empynase-P Tablets 18000
December 13, 2012
- UMN Pharma Listed on TSE Mothers, Sets Midterm Plan Target to Be in Black
December 13, 2012
- Domestic Drug Makers Need to Break from Closed Innovation and Promote Open Innovation: Prof. Teranishi of Kyoto Univ. MIC
December 13, 2012
- [Data] Sales of Takeda’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Daiichi Sankyo’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Otsuka HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Astellas’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Eisai’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Dainippon Sumitomo’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Mitsubishi Tanabe’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Taisho HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kyorin HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Shionogi’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Ono’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Santen’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kaken’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Mochida’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Nippon Shinyaku’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Zeria’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kissei’s Mainstay Products in 1st Half of FY2012
December 13, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…